Hua Ling Pharmaceuticals-B (stock code: 2552) announced its interim performance for the six months ended June 30, 2024, showing a 46.0% increase in sales revenue compared to the same period last year, reaching RMB 102.7 million. This growth is attributed to the significant increase in sales volume of the type 2 diabetes drug Huatangning®, reaching 846,000 boxes, as well as the inclusion of this drug in the national medical insurance drug list in November 2023, and its implementation for reimbursement across the country in mainland China starting from January 1, 2024. The company has collaborated with Bayer Pharmaceuticals and 80 primary distributors to promote the sales of Huatangning® in 31 provinces and direct-controlled municipalities in China. In addition, the company is conducting post-market clinical studies to evaluate the long-term safety and clinical efficacy of dorzagliatin. The company plans to further enhance production capacity and optimize operations to achieve profitability by 2025.

Hua Ling Pharmaceuticals-B (stock code: 2552) announced its interim performance for the six months ended June 30, 2024, showing a 46.0% increase in sales revenue compared to the same period last year, reaching RMB 102.7 million. This growth is attributed to the significant increase in sales volume of the type 2 diabetes drug Huatangning®, reaching 846,000 boxes, as well as the inclusion of this drug in the national medical insurance drug list in November 2023, and its implementation for reimbursement across the country in mainland China starting from January 1, 2024. The company has collaborated with Bayer Pharmaceuticals and 80 primary distributors to promote the sales of Huatangning® in 31 provinces and direct-controlled municipalities in China. In addition, the company is conducting post-market clinical studies to evaluate the long-term safety and clinical efficacy of dorzagliatin. The company plans to further enhance production capacity and optimize operations to achieve profitability by 2025.